PL3737684T3 - Pochodne 2,4,6,7-tetrahydropirazolo[4,3-d]pirymidyn-5-onu i związki pokrewne jako modulatory receptorów c5a do leczenia zapalenia naczyń i chorób zapalnych - Google Patents

Pochodne 2,4,6,7-tetrahydropirazolo[4,3-d]pirymidyn-5-onu i związki pokrewne jako modulatory receptorów c5a do leczenia zapalenia naczyń i chorób zapalnych

Info

Publication number
PL3737684T3
PL3737684T3 PL19700269.4T PL19700269T PL3737684T3 PL 3737684 T3 PL3737684 T3 PL 3737684T3 PL 19700269 T PL19700269 T PL 19700269T PL 3737684 T3 PL3737684 T3 PL 3737684T3
Authority
PL
Poland
Prior art keywords
tetrahydropyrazolo
vasculitis
pyrimidin
derivatives
treatment
Prior art date
Application number
PL19700269.4T
Other languages
English (en)
Inventor
Sylvie FROIDEVAUX
Francis Hubler
Mark Murphy
Dorte Renneberg
Simon STAMM
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of PL3737684T3 publication Critical patent/PL3737684T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Eye Examination Apparatus (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
PL19700269.4T 2018-01-10 2019-01-09 Pochodne 2,4,6,7-tetrahydropirazolo[4,3-d]pirymidyn-5-onu i związki pokrewne jako modulatory receptorów c5a do leczenia zapalenia naczyń i chorób zapalnych PL3737684T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2018050598 2018-01-10
PCT/EP2019/050372 WO2019137927A1 (en) 2018-01-10 2019-01-09 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases

Publications (1)

Publication Number Publication Date
PL3737684T3 true PL3737684T3 (pl) 2023-02-27

Family

ID=65012016

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19700269.4T PL3737684T3 (pl) 2018-01-10 2019-01-09 Pochodne 2,4,6,7-tetrahydropirazolo[4,3-d]pirymidyn-5-onu i związki pokrewne jako modulatory receptorów c5a do leczenia zapalenia naczyń i chorób zapalnych

Country Status (30)

Country Link
US (2) US11608341B2 (pl)
EP (1) EP3737684B1 (pl)
JP (1) JP7014914B2 (pl)
KR (1) KR102574564B1 (pl)
CN (1) CN111566109B (pl)
AR (1) AR114564A1 (pl)
AU (1) AU2019207666B2 (pl)
BR (1) BR112020013788A2 (pl)
CA (1) CA3086310C (pl)
CL (1) CL2020001817A1 (pl)
DK (1) DK3737684T3 (pl)
EA (1) EA202091641A1 (pl)
ES (1) ES2933820T3 (pl)
HR (1) HRP20221449T1 (pl)
HU (1) HUE060515T2 (pl)
IL (1) IL275868B2 (pl)
LT (1) LT3737684T (pl)
MA (1) MA51558B1 (pl)
MX (1) MX2020007443A (pl)
MY (1) MY198902A (pl)
PH (1) PH12020500583B1 (pl)
PL (1) PL3737684T3 (pl)
PT (1) PT3737684T (pl)
RS (1) RS63806B1 (pl)
SG (1) SG11202006490YA (pl)
SI (1) SI3737684T1 (pl)
TW (2) TWI774905B (pl)
UA (1) UA124694C2 (pl)
WO (1) WO2019137927A1 (pl)
ZA (1) ZA202004910B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11608341B2 (en) * 2018-01-10 2023-03-21 Idorsia Pharmaceuticals Ltd. Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators
CA3087784A1 (en) 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
US11739070B2 (en) 2018-01-19 2023-08-29 Idorsia Pharmaceuticals Ltd. C5A receptor modulators
UA128440C2 (uk) * 2019-07-09 2024-07-10 Ідорсія Фармасьютікалз Лтд Фармацевтична композиція, яка містить тетрагідропіразолопіримідинонову сполуку
US11193891B2 (en) * 2019-12-20 2021-12-07 Robert Bosch Gmbh Receptors and spacers for a fluorescence-based lead ion chemosensor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003218374A1 (en) 2002-03-28 2003-10-13 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
WO2004033455A2 (en) * 2002-10-08 2004-04-22 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
US7906528B2 (en) * 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US9126939B2 (en) 2010-06-24 2015-09-08 Pingchen Fan C5AR antagonists
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
TWI736135B (zh) 2013-03-01 2021-08-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
CN105705489B (zh) 2013-09-04 2019-04-26 百时美施贵宝公司 用作免疫调节剂的化合物
EP3363790B1 (en) 2013-09-06 2020-02-19 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
CA2960436C (en) * 2014-09-16 2021-01-05 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2017034872A1 (en) 2015-08-25 2017-03-02 Janssen Pharmaceutica Nv Indazole derivatives useful as cb-1 inverse agonists
US11608341B2 (en) * 2018-01-10 2023-03-21 Idorsia Pharmaceuticals Ltd. Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators
CA3087784A1 (en) 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
US11739070B2 (en) 2018-01-19 2023-08-29 Idorsia Pharmaceuticals Ltd. C5A receptor modulators
UA128440C2 (uk) 2019-07-09 2024-07-10 Ідорсія Фармасьютікалз Лтд Фармацевтична композиція, яка містить тетрагідропіразолопіримідинонову сполуку

Also Published As

Publication number Publication date
MY198902A (en) 2023-10-02
MA51558B1 (fr) 2022-12-30
EP3737684B1 (en) 2022-11-16
BR112020013788A2 (pt) 2020-12-01
EP3737684A1 (en) 2020-11-18
TW202244047A (zh) 2022-11-16
KR20200106061A (ko) 2020-09-10
TW201930307A (zh) 2019-08-01
AR114564A1 (es) 2020-09-23
IL275868A (en) 2020-08-31
HRP20221449T1 (hr) 2023-01-20
US20230192708A1 (en) 2023-06-22
MX2020007443A (es) 2020-09-14
CA3086310C (en) 2023-09-19
UA124694C2 (uk) 2021-10-27
IL275868B2 (en) 2023-06-01
JP7014914B2 (ja) 2022-02-01
CA3086310A1 (en) 2019-07-18
EA202091641A1 (ru) 2020-11-17
JP2021510373A (ja) 2021-04-22
WO2019137927A1 (en) 2019-07-18
PH12020500583A1 (en) 2021-06-14
CN111566109B (zh) 2023-07-11
PH12020500583B1 (en) 2024-02-21
ZA202004910B (en) 2024-02-28
HUE060515T2 (hu) 2023-03-28
US20200369672A1 (en) 2020-11-26
LT3737684T (lt) 2022-12-27
ES2933820T3 (es) 2023-02-14
TWI774905B (zh) 2022-08-21
TWI839788B (zh) 2024-04-21
AU2019207666A1 (en) 2020-08-27
AU2019207666B2 (en) 2023-12-21
CN111566109A (zh) 2020-08-21
SG11202006490YA (en) 2020-08-28
RS63806B1 (sr) 2023-01-31
DK3737684T3 (da) 2022-12-12
MA51558A (fr) 2021-04-14
CL2020001817A1 (es) 2020-12-04
SI3737684T1 (sl) 2023-01-31
KR102574564B1 (ko) 2023-09-04
PT3737684T (pt) 2022-12-20
US11608341B2 (en) 2023-03-21

Similar Documents

Publication Publication Date Title
PL3737684T3 (pl) Pochodne 2,4,6,7-tetrahydropirazolo[4,3-d]pirymidyn-5-onu i związki pokrewne jako modulatory receptorów c5a do leczenia zapalenia naczyń i chorób zapalnych
PL3873900T3 (pl) Imidazo[1,2-a]pirydynowe pochodne jako inhibitory integryny alpha4beta7 do leczenia chorób zapalnych
HUE064667T2 (hu) Pirido[3',4':4,5]pirrolo[1,2,3-de]kinoxalin származékok központi idegrendszeri betegségek kezelésében történõ alkalmazásra
MX2018005694A (es) 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas.
EP3500575C0 (en) CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE, ITS PREPARATION AND USES
IL270909A (en) Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptor
IL268850A (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
LT3697784T (lt) Imidazo[4,5-b]piridino junginiai ir jų farmacinės kompozicijos, skirtos uždegiminių sutrikimų gydymui
HUE057549T2 (hu) Imidazo[1,2-a]pirimidinszármazékok, eljárás elõállításukra és alkalmazásaik
IL281924A (en) New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making
AU2019410432B2 (en) Quinoline derivatives for use in the treatment of inflammation diseases
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
DK3500571T3 (da) Imidazo[1,2-a]pyridinforbindelser, sammensætninger omfattende disse, fremgangsmåder til behandling af sygdomme ved hjælp af disse og fremgangsmåder til fremstilling heraf
EP3709998B8 (en) N-[5-(imidazo[1,2-a]pyrimidin-2-yl)phenyl]-benzamide and -benzeneacetamide derivatives as tnf stimulators for the treatment of e.g. infectious diseases and cancer
IL264603A (en) Reelin compositions for treatment of neurological disorders
EP3679042A4 (en) IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS
PL3894411T3 (pl) Pochodne 7-fenoksy-N-(3-azabicyklo[3.2.1]oktan-8-ylo)-6,7-dihydro-5H-pirolo[1,2-b][1,2,4]triazolo-2-aminy i związki pokrewne jako modulatory gamma-sekretazy do leczenia choroby Alzheimera
HRP20180788T1 (hr) [1,2,4]triazolo[4,3-b]piridazini za uporabu za liječenje proliferativnih bolesti
EP4051387C0 (en) HYDROPYRAZINO[1,2-D][1,4]DIAZEPINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
HUE047822T2 (hu) Immun- vagy gyulladásos betegségek és rák kezelésére alkalmas 7-(morfolin-4-il)pirazol[1,5-a]pirimidin-származékok
IL270927B (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
PL3597648T3 (pl) METODA WYTWARZANIA 3,6-DIPODSTAWIONEJ POCHODNEJ IMIDAZO[1, 2-b]PIRYDAZYNY
EP3854401A4 (en) PURINE DERIVATIVES CDC7 INHIBITORS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL PATHOLOGIES
EP3634395A4 (en) LIXIVAPTAN FORMULATIONS FOR THE TREATMENT OF POLYKYSTOSIS
GB201918444D0 (en) The integration platform of the community system